Evaluating the efficacy of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer

Evaluating the efficacy of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer

Purpose Triple negative breast cancer (TNBC) is characterized by the presence of immune cells in the tumor microenvironment, however, the response to single-agent immune checkpoint inhibitor (ICI) therapy is modest. Preclinical models have demonstrated that intratumoral regulatory T cells (Tregs) da...

Full description

Saved in:
Bibliographic Details
Main Authors: Karen McKinnon, Kristen Cowens, Dante Bortone, Lisa Carey, Trevor Jolly, Hyman Muss, Katherine Reeder-Hayes, Rebecca Kaltman, Rachel Jankowitz, Vinay Gudena, Oludamilola Olajide, Charles Perou, Carey K Anders, Mark G Woodcock, Amanda E D Van Swearingen, Dominic T Moore, Maria J Sambade, Sonia Laurie, Alexander Robeson, Oleg Kolupaev, Luz A Cuaboy, Amy L Garrett, Benjamin C Calhoun, Alec D Wilkinson, E Claire Dees, Benjamin G Vincent, Jonathan S Serody
Format: Article
Language:English
Published: BMJ Publishing Group 2022-02-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/10/2/e003427.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://jitc.bmj.com/content/10/2/e003427.full

Similar Items